Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test

American Journal of Gastroenterology

Volumn 108, Issue 1, 2013, Pages 83-89

  Nakarai, Asuka ^a   Kato, Jun ^b   Hiraoka, Sakiko ^a   Kuriyama, Motoaki ^c   Akita, Mitsuhiro ^a   Hirakawa, Tomoko ^a   Okada, Hiroyuki ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c Department of Internal Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; HEMOGLOBIN; MERCAPTOPURINE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COLON MUCOSA; COLONOSCOPY; COLORECTAL TUMOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; FECAL IMMUNOCHEMICAL TEST; FEMALE; HEALING; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBINS; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; OCCULT BLOOD; PROPORTIONAL HAZARDS MODELS; RECTUM; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872006041     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.315     Document Type: Article

References (26)

1. Head KA, Jurenka JS. Inflammatory bowel disease Part 1: ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev 2003; 8: 247-83.
2. Turner D, Walsh CM, Steinhart AH et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-10.
3. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29.
4. Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
5. Ardizzone S, Cassinotti A, Duca P et al. Mucosal healing predicts late outcomes aft er the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-9 e3.
6. Menees S, Higgins P, Korsnes S et al. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm Bowel Dis 2007; 13: 12-8.
7. Gisbert JP, Bermejo F, Perez-Calle JL et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190-8.
8. Vilkin A, Rozen P, Levi Z et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005; 100: 2519-25.
9. Levi Z, Rozen P, Hazazi R et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146: 244-55.
10. van Rossum LG, van Rijn AF, Laheij RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90.
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
12. Kuriyama M, Kato J, Takemoto K et al. Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test. World J Gastroenterol 2010; 16: 1110-4.
13. Chen LS, Yen AM, Chiu SY et al. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011; 12: 551-8.
14. Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295-301.
15. Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8; quiz e10-1.
16. Froslie KF, Jahnsen J, Moum BA e t al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22.
17. Rutter MD, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-6.
18. Gupta RB, Harpaz N, Itzkowitz S et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-105; quiz 1340-1.
19. Karoui S, Laz S, Serghini M et al. Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis. Dig Dis Sci 2011; 56: 1801-5.
20. Schoepfer AM, Beglinger C, Straumann A et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15: 1851-8.
21. Hol L, Wilschut JA, van Ballegooijen M et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009; 100: 1103-10.
22. Costa F, Mumolo MG, Bellini M et al. Role of faecal calprotectin as noninvasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-7.
23. Nakama H, Yamamoto M, Kamijo N et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999; 46: 228-31.
24. Nakama H, Zhang B, Fattah AS. A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer. Eur J Cancer 2000; 36: 647-50.
25. Wong BC, Wong WM, Cheung KL et al. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther 2003; 18: 941-6.
26. Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-9.